Correlating physicochemical and biological properties to define critical quality attributes of a recombinant AAV vaccine candidate
Author:
Kumar Prashant,Wang Michael,Kumru Ozan S.,Hickey John,Sanmiguel Julio,Zabaleta Nerea,Vandenberghe Luk H.,Joshi Sangeeta B.,Volkin David B.
Abstract
AbstractRecombinant adeno-associated viruses (rAAVs) are a preferred vector system in clinical gene transfer. A fundamental challenge to formulate and deliver rAAVs as stable and efficacious vaccines is to elucidate interrelationships between the vector’s physicochemical properties and biological potency. To this end, we evaluated an rAAV-based COVID-19 vaccine candidate which encodes the Spike antigen (AC3) and is produced by an industrially-compatible process. First, state-of-the-art analytical techniques were employed to determine key structural attributes of AC3 including primary and higher-order structures, particle size, empty/full capsid ratios, aggregates and multi-step thermal degradation pathway analysis. Next, several quantitative potency measures for AC3 were implemented and data were correlated with the physicochemical analyses on thermal-stressed and control samples. Results demonstrate links between decreasing AC3 physical stability profiles,in vitrotransduction efficiency in a cell-based assay, and importantly,in vivoimmunogenicity in a mouse model. These findings are discussed in the general context of future development of rAAV-based vaccines candidates as well as specifically for the rAAV vaccine application under study.
Publisher
Cold Spring Harbor Laboratory
Reference109 articles.
1. WHO (2022). Timeline: WHO’s COVID-19 response. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline.
2. WHO (2020). COVID-19 Public Health Emergency of International Concern (PHEIC) Global research and innovation forum. https://www.who.int/publications/m/item/covid-19-public-health-emergency-of-international-concern-(pheic)-global-research-and-innovation-forum.
3. Operation Warp Speed: Accelerated COVID-19 Vaccine Development Status and Efforts to Address Manufacturing Challenges. (2021). https://www.gao.gov/products/gao-21-319.
4. SARS-CoV-2 mRNA vaccination elicits robust antibody responses in children